Ingalls & Snyder LLC lowered its position in shares of Vericel Corp (NASDAQ:VCEL) by 2.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 58,007 shares of the biotechnology company’s stock after selling 1,245 shares during the period. Ingalls & Snyder LLC’s holdings in Vericel were worth $1,009,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also recently made changes to their positions in VCEL. Royal Bank of Canada increased its holdings in shares of Vericel by 665.8% during the 2nd quarter. Royal Bank of Canada now owns 1,547 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,345 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new stake in shares of Vericel during the 3rd quarter worth approximately $61,000. Meeder Asset Management Inc. increased its holdings in shares of Vericel by 238,766.7% during the 3rd quarter. Meeder Asset Management Inc. now owns 7,166 shares of the biotechnology company’s stock worth $108,000 after buying an additional 7,163 shares during the last quarter. Virginia Retirement Systems ET AL increased its holdings in shares of Vericel by 7.2% during the 3rd quarter. Virginia Retirement Systems ET AL now owns 14,900 shares of the biotechnology company’s stock worth $226,000 after buying an additional 1,000 shares during the last quarter. Finally, Conestoga Capital Advisors LLC acquired a new stake in shares of Vericel during the 3rd quarter worth approximately $251,000. Institutional investors and hedge funds own 86.86% of the company’s stock.
NASDAQ:VCEL opened at $17.00 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.48 and a current ratio of 6.93. The stock has a market capitalization of $737.02 million, a P/E ratio of -121.43 and a beta of 2.67. The company has a 50 day moving average price of $17.68 and a 200 day moving average price of $17.28. Vericel Corp has a fifty-two week low of $13.40 and a fifty-two week high of $21.00.
Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.09. The firm had revenue of $30.50 million during the quarter, compared to analysts’ expectations of $26.84 million. Vericel had a negative net margin of 12.68% and a positive return on equity of 3.66%. The firm’s quarterly revenue was up 35.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.02) EPS. Research analysts forecast that Vericel Corp will post 0.16 earnings per share for the current fiscal year.
VCEL has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Vericel in a research report on Tuesday, November 5th. Zacks Investment Research raised shares of Vericel from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research report on Wednesday. HC Wainwright initiated coverage on shares of Vericel in a research report on Wednesday, October 9th. They set a “buy” rating and a $19.00 price objective for the company. ValuEngine raised shares of Vericel from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Finally, BidaskClub cut shares of Vericel from a “sell” rating to a “strong sell” rating in a research report on Friday, January 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $22.18.
In related news, COO Michael Halpin sold 15,047 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $18.53, for a total transaction of $278,820.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.50% of the company’s stock.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
Featured Story: Penny Stocks, What You Need To Know
Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corp (NASDAQ:VCEL).
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.